AstraZeneca (AZN) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 core EPS of $2.52, up from $2.49 in Q1 2025.
• Consensus revenue forecast around $14.8 billion, reflecting mid-single-digit growth at constant exchange rates (CER).
• FY 2026 guidance reiterated: mid-to-high single-digit total revenue growth and low double-digit core EPS growth at CER.
• Key watches include oncology momentum, China volume-based procurement (VBP) impacts, and pipeline updates with over 20 Phase 3 readouts expected in 2026.
• Historical stock reactions to earnings have been positive in most cases, with shares rising post-report 10 out of 12 times.

Earnings Context and Why It Matters

AstraZeneca's Q1 2026 earnings, covering January to March, arrive amid sustained momentum from 2025's 8% total revenue growth to $58.7 billion at CER and 11% core EPS rise to $9.16. Oncology drove much of the performance, with blockbusters like Tagrisso and Enhertu leading 17% segment growth. Investors eye this report for early signs of FY 2026 guidance execution, especially amid China VBP price cuts on Forxiga and Lynparza, Japan pricing revisions, and U.S. manufacturing expansions. Broader biopharma pressures from biosimilars and policy shifts heighten focus on AstraZeneca's diversified portfolio and pipeline, positioning it toward the $80 billion revenue ambition by 2030.

Earnings Expectations

Wall Street consensus pegs Q1 2026 core EPS at $2.52, a slight increase from $2.49 in Q1 2025 when total revenue hit $13.6 billion (up 10% at CER). Revenue estimates hover around $14.8 billion, implying roughly 9% growth, aligned with FY guidance for mid-to-high single-digit total revenue expansion at CER. Analysts anticipate strength in oncology (e.g., Imfinzi up 37% in Q4 2025) offsetting headwinds like Forxiga generics in ex-U.S. markets and China VBP reductions. Core operating profit growth is eyed at low double-digits, supported by stable gross margins (~82%) and disciplined SG&A.

Company guidance for FY 2026 remains unchanged: total revenue mid-to-high single-digit growth, core EPS low double-digits at CER, with core tax rate 18-22%. Pipeline catalysts, including EMERALD-3 and DESTINY trials, could influence outlook. Historically, AstraZeneca has beaten core EPS estimates, as in Q1 2025, though stock moves average modest post-earnings.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

Sentiment heading into Q1 2026 is cautiously optimistic, buoyed by FY 2025 beats and robust FY guidance. Shares have gained post-earnings historically, up in 10 of 12 prior reports, though Q4 2025's slight core EPS miss led to muted response. Risks include China pricing pressures and biosimilar erosion (e.g., Soliris down 26% in Q4), but oncology resilience and 20+ Phase 3 readouts fuel positivity. Options imply ~4-5% volatility around the April 29 release.

Forward Outlook and Key Factors to Monitor

Post-Q1, investors should track progress against FY 2026 guidance, with mid-to-high single-digit revenue growth at CER and low double-digit core EPS expansion. Oncology remains the engine, but watch China VBP effects on Forxiga (20% cut), Lynparza (30%), and roxadustat, plus Japan revisions from April (Forxiga -36%).

Pipeline momentum is critical, with H1 2026 catalysts like EMERALD-3 (Tagrisso in NSCLC), VOLGA (Imfinzi in bladder), and others potentially driving label expansions and revenue uplift. Manufacturing investments, including U.S. sites and Singapore ADC facility, support long-term capacity amid policy shifts like MFN and tariff delays.

Cash flow dynamics merit attention: operating inflows strong at $14.6 billion in FY 2025, but CapEx rises ~33% in 2026 (~$4.4 billion), BD deals (~$2.5 billion), and dividends ($3.30/share intent). Net debt/EBITDA at 1.2x provides flexibility. Core R&D at upper low-20%s of revenue sustains innovation toward 2030 goals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations